Roquefort Therapeutics (LON:ROQ) Shares Up 4.1% – Still a Buy?

Roquefort Therapeutics plc (LON:ROQ)’s stock price rose 4.1% during mid-day trading on Monday . The company traded as high as GBX 4.40 ($0.06) and last traded at GBX 4.40 ($0.06). Approximately 1,792,901 shares were traded during mid-day trading, an increase of 253% from the average daily volume of 508,240 shares. The stock had previously closed at GBX 4.23 ($0.05).

Roquefort Therapeutics Stock Down 5.7 %

The company has a quick ratio of 3.07, a current ratio of 0.79 and a debt-to-equity ratio of 12.37. The company has a market capitalization of £5.30 million, a P/E ratio of -420.00 and a beta of 0.05. The firm has a fifty day simple moving average of GBX 3.95 and a 200-day simple moving average of GBX 4.27.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics plc, a biotechnology company, engages in the development of medicines for the treatment of cancer. The company's pre-clinical development pipeline comprises Midkine antibodies with significance in vivo efficacy and toxicology studies; Midkine RNA therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics with novel anti-cancer approach; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and NK-mediated anti-cancer action.